Blood tests may spot transplant rejection early
NCT ID NCT04855422
First seen Jan 05, 2026 · Last updated Jun 12, 2026 · Updated 27 times
Summary
This study looks at two blood tests, AlloSure and AlloMap, to see if they can help doctors predict or confirm organ rejection in people who have received both a kidney and a pancreas transplant. The study will follow 42 patients for up to three years after their transplant. The goal is to find a less invasive way to monitor transplant health compared to standard biopsies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRANSPLANT; COMPLICATION, REJECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Montefiore Medical Center
The Bronx, New York, 10461, United States
Conditions
Explore the condition pages connected to this study.